All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DBPR115
Therapeutic Area: Oncology Product Name: DBPR115
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
DBPR115 small molecule drug delivery system has a lower production cost and is less likely to cause adverse immune reactions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ridgeback Capital Investments
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 16, 2021
Details:
The funding will be used to advance the company’s lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pidnarulex
Therapeutic Area: Oncology Product Name: CX-5461
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2020
Details:
In the CCTG Trial, CX-5461 demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OBI-833
Therapeutic Area: Oncology Product Name: OBI-833
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
In the trial, OBI-833 showed a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. The company’s novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin and OBI-833, a Globo H active immunotherapy vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
ACE1702 displayed higher cytotoxicity against multiple HER2-expressing cancer cell lines compared to the leading anti-HER2 antibody, trastuzumab, and its derived antibody-drug conjugate, trastuzumab emtansine (T-DM1).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Poster titled A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment will be presented at the at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
The study will evaluate the safety and tolerability, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing solid tumors not amenable to surgery or other therapeutic options.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
